Abstract
Despite the great potential of CRISPR-based detection, it has not been competitive with other market diagnostics for on-site and in-home testing. Here we dissect the rate-limiting factors that undermine the performance of Cas12b- and Cas13a-mediated detection. In one-pot testing, Cas12b interferes with loop-mediated isothermal amplification by binding to and cleaving the amplicon, while Cas13a directly degrades the viral RNA, reducing its amplification. We found that the protospacer-adjacent motif-interacting domain engineered Cas12b accelerated one-pot testing with 10–10,000-fold improved sensitivity, and detected 85 out of 85 SARS-CoV-2 clinical samples with a sensitivity of 0.5 cp μl−1, making it superior to wild-type Cas12b. In parallel, by diminishing the interference of Cas13a with viral RNA, the optimized Cas13a-based assay detected 86 out of 87 SARS-CoV-2 clinical samples at room temperature in 30 min with a sensitivity of 0.5 cp μl−1. The relaxed reaction conditions and improved performance of CRISPR-based assays make them competitive for widespread use in pathogen detection.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Source data are provided with this paper.
References
Kuiken, T. et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263–270 (2003).
Zhong, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 362, 1353–1358 (2003).
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New Engl. J. Med. 367, 1814–1820 (2012).
Chang, S. Y., Bowman, B. H., Weiss, J. B., Garcia, R. E. & White, T. J. The origin of HIV-1 isolate HTLV-IIIB. Nature 363, 466–469 (1993).
Dietrich, U. et al. A highly divergent HIV-2-related isolate. Nature 342, 948–950 (1989).
Piot, P., Muyembe, J. J. & Edmunds, W. J. Ebola in west Africa: from disease outbreak to humanitarian crisis. Lancet. Infect. Dis. 14, 1034–1035 (2014).
Petersen, L. R., Jamieson, D. J., Powers, A. M. & Honein, M. A. Zika virus. New Engl. J. Med. 374, 1552–1563 (2016).
Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021).
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl. J. Med. 382, 727–733 (2020).
Chen, Y. et al. Emerging SARS-CoV-2 variants: why, how, and what’s next? Cell Insight 1, 100029 (2022).
Safiabadi Tali, S. H. et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin. Microbiol. Rev. 34, e00228-20 (2021).
Osório, N. S. & Correia-Neves, M. Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays. Lancet Infect. Dis. 21, 166–167 (2020).
Blairon, L., Piteüs, S., Beukinga, I. & Tré-Hardy, M. Development and implementation of a RT-qPCR extraction-free protocol for the detection of SARS-CoV-2 and impact on the turn-around-time. J. Med. Virology 93, 2538–2542 (2021).
Vogels, C. B. F. et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat. Microbiol. 5, 1299–1305 (2020).
Freire-Paspuel, B. & Garcia-Bereguiain, M. A. Analytical sensitivity and clinical performance of a triplex RT-qPCR assay using CDC N1, N2, and RP targets for SARS-CoV-2 diagnosis. Int. J. Infect. Dis. 102, 14–16 (2021).
Albert, E. et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin. Microbiol. Infection 27, 472.e7–472.e10 (2021).
Corman, V. M. et al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. Lancet. Microbe 2, e311–e319 (2021).
Mak, G. C. et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J. Clin. Virol. 129, 104500 (2020).
Torres, I., Poujois, S., Albert, E., Colomina, J. & Navarro, D. Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. Clin. Microbiol. Infect. 27, 636.e1–636.e4 (2021).
Piepenburg, O., Williams, C. H., Stemple, D. L. & Armes, N. A. DNA detection using recombination proteins. PLoS Biol. 4, e204 (2006).
Park, G. S. et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J. Mol. Diagn. 22, 729–735 (2020).
Baek, Y. H. et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg. Microbes Infect. 9, 998–1007 (2020).
Cherkaoui, D., Huang, D., Miller, B. S., Turbé, V. & McKendry, R. A. Harnessing recombinase polymerase amplification for rapid multi-gene detection of SARS-CoV-2 in resource-limited settings. Biosens. Bioelectron. 189, 113328 (2021).
Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F. & Collins, J. J. CRISPR-based diagnostics. Nat. Biomed. Eng. 5, 643–656 (2021).
Freije, C. A. & Sabeti, P. C. Detect and destroy: CRISPR-based technologies for the response against viruses. Cell Host Microbe 29, 689–703 (2021).
Liu, T. Y. et al. Accelerated RNA detection using tandem CRISPR nucleases. Nat. Chem. Biol. 17, 982–988 (2021).
Yang, L.-Z. et al. Multi-color RNA imaging with CRISPR-Cas13b systems in living cells. Cell Insight 1, 100044 (2022).
Qiu, H.-Y., Ji, R.-J. & Zhang, Y. Current advances of CRISPR-Cas technology in cell therapy. Cell Insight 1, 100067 (2022).
Chen, J. S. et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 360, 436–439 (2018).
Li, S. Y. et al. CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA. Cell Res. 28, 491–493 (2018).
Teng, F. et al. CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity. Genome Biol. 20, 132 (2019).
East-Seletsky, A. et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature 538, 270–273 (2016).
Fozouni, P. et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 184, 323–333.e329 (2021).
Swarts, D. C. & Jinek, M. Mechanistic insights into the cis- and trans-acting DNase activities of Cas12a. Mol. Cell 73, 589–600.e4 (2019).
East-Seletsky, A., O’Connell, M. R., Burstein, D., Knott, G. J. & Doudna, J. A. RNA targeting by functionally orthogonal type VI-A CRISPR-Cas enzymes. Mol. Cell 66, 373–383.e3 (2017).
Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356, 438–442 (2017).
Myhrvold, C. et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science 360, 444–448 (2018).
Broughton, J. P. et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 38, 870–874 (2020).
Patchsung, M. et al. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat. Biomed. Eng. 4, 1140–1149 (2020).
Arizti-Sanz, J. et al. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat. Commun. 11, 5921 (2020).
Joung, J. et al. Detection of SARS-CoV-2 with SHERLOCK one-pot testing. New Engl. J. Med. 383, 1492–1494 (2020).
Lu, S. et al. Fast and sensitive detection of SARS-CoV-2 RNA using suboptimal protospacer adjacent motifs for Cas12a. Nat. Biomed. Eng. 6, 286–297 (2022).
Chandrasekaran, S. S. et al. Rapid detection of SARS-CoV-2 RNA in saliva via Cas13. Nat. Biomed. Eng. 6, 944–956 (2022).
Arizti-Sanz, J. et al. Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants. Nat. Biomed. Eng. 6, 932–943 (2022).
Nakauchi, M. et al. Evaluation of reverse transcription loop-mediated isothermal amplification assays for rapid diagnosis of pandemic influenza A/H1N1 2009 virus. J. Med. Virol. 83, 10–15 (2011).
Hatano, B. et al. Mobile and accurate detection system for infection by the 2009 pandemic influenza A (H1N1) virus with a pocket-warmer reverse-transcriptase loop-mediated isothermal amplification. J. Med. Virol. 83, 568–573 (2011).
Yang, H., Gao, P., Rajashankar, K. R. & Patel, D. J. PAM-dependent target DNA recognition and cleavage by C2c1 CRISPR-Cas endonuclease. Cell 167, 1814–1828.e12 (2016).
Lai, M. Y. et al. Colorimetric detection of SARS-CoV-2 by uracil-DNA glycosylase (UDG) reverse transcription loop-mediated isothermal amplification (RT-LAMP). Int. J. Infect. Dis. 120, 132–134 (2022).
Qian, C. et al. Uracil-mediated new photospacer-adjacent motif of Cas12a to realize visualized DNA detection at the single-copy level free from contamination. Anal. Chem. 91, 11362–11366 (2019).
Minetti, C., Lacourse, E. J., Reimer, L. & Stothard, J. R. Focusing nucleic acid-based molecular diagnostics and xenomonitoring approaches for human helminthiases amenable to preventive chemotherapy. Parasitol. Open 2, e16 (2016).
Sam, I. K. et al. TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive detection of Mycobacterium tuberculosis. J. Infect. 83, 54–60 (2021).
Rödel, J. et al. Use of the Variplex™ SARS-CoV-2 RT-LAMP as a rapid molecular assay to complement RT-PCR for COVID-19 diagnosis. J. Clin. Virol. 132, 104616 (2020).
De Felice, M., De Falco, M., Zappi, D., Antonacci, A. & Scognamiglio, V. Isothermal amplification-assisted diagnostics for COVID-19. Biosens. Bioelectron. 205, 114101 (2022).
Yang, J. et al. Engineered LwaCas13a with enhanced collateral activity for nucleic acid detection. Nat. Chem. Biol. 19, 45–54 (2022).
Brown, M. D. & Schoenfisch, M. H. Electrochemical nitric oxide sensors: principles of design and characterization. Chem. Rev. 119, 11551–11575 (2019).
Shi, Y. J. et al. DNA topology regulates PAM-Cas9 interaction and DNA unwinding to enable near-PAMless cleavage by thermophilic Cas9. Mol. Cell 82, 4160–4175.e6 (2022).
Zhang, H.-X. et al. Cas12a-based one-pot SNP detection with high accuracy. Cell Insight 2, 100080 (2023).
Acknowledgements
This work is kindly supported by Key R&D Program of Hubei Province (grant nos. 2022BCA089 to H.Y. and 2022ACA005 to Y.Z.), National Key R&D Program of China (grant nos. 2019YFA0802801, 2018YFA0801401 and 2022YFF1002801), the Ministry of Agriculture and Rural Affairs of China, the Strategic Priority Research Program of CAS (grant no. XDB29010300 to X.Z.), the National Natural Science Foundation of China (grant nos. 31871345 and 32071442 to H.Y., 31972936 to Y.Z. and 31970169 to X.Z.), State Key Laboratory for Animal Disease Control and Prevention (SKLVBF202202), Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (grant no. TFJC2018004), the Fundamental Research Funds for the Central Universities (grant nos. 2042022dx0003 and 2042022kf1190), Applied Basic Frontier Program of Wuhan City (grant no. 2020020601012216 to H.Y.) and the startup funding from Wuhan University (to H.Y. and Y.Z.). We thank the core facility of Medical Research Institute at Wuhan University for their technical supports. We thank Wuhan Easy Diagnosis Biomedicine Co. for providing some reagents.
Author information
Authors and Affiliations
Contributions
H.Y. conceived, designed and managed the project. X.T. and K.Z. performed most experiments with the help of T.L., M.D. and R.J. X.T. engineered the Cas12b protein and developed a room temperature REVERSE method. X.T., K.Z. and T.L. developed one-pot testing mediated by Cas12b-mutants. X.T., K.Z. and T.L. optimized conditions for detecting viral samples. Y.Z. provided conceptual advice. X.Z., X.W. and Y.H. provided samples, and Y.H. performed related experiments. X.T. and H.Y. analyzed the data. H.Y., Y.Z. and X.T. wrote the paper with inputs from the authors.
Corresponding author
Ethics declarations
Competing interests
H.Y., Y.Z., X.T., K.Z. and T.L. have filed a patent application (no. 202311783425.X) through Wuhan University. The other authors declare no competing interests.
Peer review
Peer review information
Nature Chemical Biology thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Comparison of Cas12b-mediated one-pot testing using canonical PAM or suboptimal PAMs.
(a–f) The fluorescence curves of one-pot testing using canonical PAM or suboptimal PAMs of Cas12b. For a-c, the one-pot testing was mediated by LAMP. For d-f, the one-pot testing was mediated by RPA. Mean ± s.d. for 3 technical replicates.
Extended Data Fig. 2 Sequences of AapCas12b.
Conservative analysis of residues 478 and 396 between Cas12b orthologs.
Extended Data Fig. 3 Cis-cleavage of Cas12b variants.
Cis-cleavage of Cas12b-WT, Cas12b-2M, enzymatically dead Cas12b-WT, and enzymatically dead Cas12b-2M. Enzymatically dead indicates E848A (ref. 45). Proteinase K was introduced to stop reaction at various time points. The experiment was repeated twice with similar results. S, 1241 bp substrate; P1 and P2, 927 bp product 1 and 314 bp product 2.
Extended Data Fig. 4 Optimization of one-pot testing.
(a) The performance of commercially available bst enzymes were determined in one-pot testing at 60 °C. Bst1-7 represent bst 2.0 DNA polymerase (NEB), bst 3.0 DNA polymerase (NEB), bst DNA polymerase from Vazyme, Beyotime, FAPON-BIOTECH, YEASEN and bst DNA polymerase Plus from YEASEN. (b) The optimized one-pot testing using Cas12b-2M or WT. ‘cp/µL’ indicates the copy number per microliter in one-pot testing. For a & b, mean ± s.d. for 3 technical replicates. (c) LAMP alone tests of SARS-CoV-2 clinical samples.
Extended Data Fig. 5 The fluorescence curves in one-pot testing with or without UNG.
(a-b) The fluorescence curves of one-pot testing with or without UNG were identified. The Ct values of clinical samples 1-6 were 23.8, 23.5, 22.6, 27.0, 33.5, and 29.0, respectively. Mean ± s.d. of n = 3 technical replicates.
Extended Data Fig. 6 Performance of REVERSE in detecting SARS-CoV-2.
(a) Sensitivity comparison between REVERSE and SHINE. The black dotted line represents the threshold, which was determined as three times the negative control fluorescence value. (b, c) Evaluation of REVERSE-2 performance at 20 °C using a fluorescence reader (b) and blue light (c). (d) Comparison of Cas13a-, Cas12a- and Cas12b-mediated one-pot testing at 20 °C and 25 °C. The input substrates comprised pseudo-SARS-CoV-2 RNA of 1 cp/μL. Results were captured using blue light at 30, 40, 50, and 60 minutes. Mean ± s.d. for 4 technical replicates for a; 3 technical replicates for b.
Extended Data Fig. 7 Sensitivity and specificity comparison between REVERSE-2 and antigen test at room temperature.
(a, b) Sensitivity assessment of REVERSE-2 (a) and the antigen test (b). (c, d) Determination of the specificity of REVERSE-2 and the antigen test.
Supplementary information
Supplementary Information
Supplementary Tables 1–6.
Source data
Source Data Figs. 1–4 and Extended Data Figs. 1 and 4–6.
Statistical source data.
Source Data Fig. 3
Unprocessed gels.
Source Data Fig. 4
Unprocessed gels.
Source Data Extended Data Fig. 3
Unprocessed gels.
Source Data Extended Data Fig. 6
Unprocessed gels.
Source Data Extended Data Fig. 7
Unprocessed gels.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tong, X., Zhang, K., Han, Y. et al. Fast and sensitive CRISPR detection by minimized interference of target amplification. Nat Chem Biol 20, 885–893 (2024). https://doi.org/10.1038/s41589-023-01534-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-023-01534-9